Should You Buy Ladbrokes PLC Instead Of AstraZeneca plc & International Consolidated Airlins Grp SA?

Could Ladbrokes PLC (LON: LAD) outperform the likes of AstraZeneca plc (LON: AZN) and International Consolidated Airlins Grp SA (LON: IAG)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in betting firm Ladbrokes (LSE: LAD) have fallen by just 0.5% today despite the company reporting a hugely disappointing set of first half results. In fact, it has swung from a pretax profit in the first half of 2014 to a pretax loss in the first half of 2015, with shop closures and impairments contributing to a £51m pretax loss in the six months to June 30.

Clearly, this is hugely disappointing for the company’s investors and, while Ladbrokes has been touted as a strong dividend play owing to its relatively high yield, dividends have understandably been slashed. The company will now pay out 1p per share in its interim dividend, which is well down on the 4.3p per share that was paid in the first six months of last year.

Of course, the gaming industry is enduring a highly challenging period, with competition being very high and margins being squeezed. As such, sector consolidation is inevitable and Ladbrokes’ planned merger with Coral seems to make a lot of sense due to potential synergies and efficiencies that can be made. However, the road to recovery will be a challenging one and, while shares in Ladbrokes have already fallen by 16% in the last year, there could be further falls to come. As such, now does not appear to be the right time to buy a slice of the company.

However, there are a number of stunning investment opportunities within the FTSE 350. Notably, pharmaceutical company AstraZeneca (LSE: AZN) appears to offer a very bright future of growth and, while it has endured a difficult period in recent years as a result of the loss of patents, it is expected to begin delivering growth in the next few years.

Undoubtedly, AstraZeneca is not yet the finished product, with further acquisitions required in order to improve its pipeline. However, the strategy being adopted by the business is very sound and has seen AstraZeneca focus on treatments for health issues such as diabetes, which are expected to become major global challenges in the long run. Therefore, it is positioning itself for excellent long term growth and, even though a bid approach is less likely following the closing of a US tax loophole, its yield of 4.1% and price to earnings (P/E) ratio of 15.9 continue to indicate that it is a very strong buy.

Similarly, IAG (LSE: IAG), owner of British Airways, has also struggled to post strong financial numbers in recent years. For example, it made a loss in 2012 but, with an improving global economy and lower oil price positively impacting sales and costs respectively, its profitability is on the rise. For example, IAG is forecast to increase its bottom line by 75% this year and by a further 20% next year. This could improve investor sentiment moving forward and, even though IAG has posted a share price rise of 67% in the last year, its price to earnings growth (PEG) ratio of just 0.2 indicates that there could be further growth to come.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Female student sitting at the steps and using laptop
Investing Articles

How much do you need in an ISA to target £8,333 a month of passive income?

Our writer explores a potential route to earning double what is today considered a comfortable retirement and all tax-free inside…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Could these 3 FTSE 100 shares soar in 2026?

Our writer identifies a trio of FTSE 100 shares he thinks might potentially have more petrol in the tank as…

Read more »

Pakistani multi generation family sitting around a table in a garden in Middlesbourgh, North East of England.
Dividend Shares

How much do you need in a FTSE 250 dividend portfolio to make £14.2k of annual income?

Jon Smith explains three main factors that go into building a strong FTSE 250 dividend portfolio to help income investors…

Read more »

Tesla building with tesla logo and two teslas in front
Investing Articles

275 times earnings! Am I the only person who thinks Tesla’s stock price is over-inflated?

Using conventional measures, James Beard reckons the Tesla stock price is expensive. Here, he considers why so many people appear…

Read more »

Investing Articles

Here’s what I think investors in Nvidia stock can look forward to in 2026

Nvidia stock has delivered solid returns for investors in 2025. But it could head even higher in 2026, driven by…

Read more »

Investing Articles

Here are my top US stocks to consider buying in 2026

The US remains the most popular market for investors looking for stocks to buy. In a crowded market, where does…

Read more »

Investing Articles

£20,000 in excess savings? Here’s how to try and turn that into a second income in 2026

Stephen Wright outlines an opportunity for investors with £20,000 in excess cash to target a £1,450 a year second income…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

Is a 9% yield from one of the UK’s most reliable dividend shares too good to be true?

Taylor Wimpey’s recent dividend record has been outstanding, but investors thinking of buying shares need to take a careful look…

Read more »